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About oral absorption and human pharmacokinetics of chondroitin sulfateDear Editor,
A recent paper by Jackson et al.1 investigates the pharmacoki-
netics (PK) of glucosamine (GlcN) and chondroitin sulfate (CS)
when taken separately or in combination as a single dose. As
concerns CS, the authors report that the endogenous concentration
and CS disaccharide composition were not detectably altered by
ingestion of CS. As a consequence, the authors state “we found no
evidence for absorption of oral CS into the circulation under any
dosing regimen”.
However, many previous studies on man [see Refs. 2 and 3],
animals4 and in vitromodels5 using CS or similar natural biomacro-
molecules, i.e., dermatan sulfate, desulfated CS, fucosyl CS, heparin,
or mixtures [see Refs. 2 and 3] clearly demonstrated the oral
absorption of these polysaccharides. As a consequence, how is it
possible to explain the “absence” of CS oral absorption in man
observed in1? The key point is related to the study protocol and
analytical procedures andmethodologies adopted in their research.
This is more important when oral PK and bioavailability of highly
structurally complex and heterogeneous macromolecules like CS
are under investigation. This is more complexwhen studies are per-
formed on human biological ﬂuids, such as plasma, inwhich endog-
enous CS is present2,3, and a large individual variability is expected.
Keeping this in mind, we should consider that two PK studies
have been performed on oral absorption of CS. To this aim,
4000 mg of CS were orally administered to 20 human volunteers2,3.
According to these studies, a total absorption of 2.5–5% (mean
w3.5%) CS was observed. Considering that Jackson et al. performed
their study on 1200 mg CS1, that the total blood volume in a man is
w1/12 of his weight6 and that plasma constitutes w55% of the
entire blood6, and that the recovery obtained in1 is w75%, we can
calculate a maximum of CS absorption of w10–15 mg/mL plasma,
possibly evaluated under a curve between 2 and 6 h, as demon-
strated for a similar CS2. As a consequence, the possible increase
of a single concentration-time between 2 and 6 h in1 blood sample
obtained at 2, 2.5, 3, 4 and 6 h along with other points may be
expected at a maximum of 4–8 mg/mL. Under these conditions
and considering that Jackson et al. determined a mean CS endoge-
nous concentration of approx. 20 mg/mL with a possible individual
variation of 5 mg/mL (25%) and 40–45% variation in AUC values after
CS administration (see Tables IV and VI)1 (similar values to those
obtained in studies Refs. 2, 3), it is hard to obtain any signiﬁcant
plasma CS variation. To conﬁrm this, a trend toward higher CS
concentrations was observed by the authors but differences were
found to be non-signiﬁcant, also perhaps due to the small number
of subjects, 9–10, studied1.
Closely related to the ﬁrst point, is the possibility to determine
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ride (generally present in endogenous CS plasma in trace
amounts)2,3. In fact, in previous studies2,3 a maximum increase of
w20% of Di6s was observed after administration of 4000 mg CS.
By performing the same approach as previously reported, we can
expect a maximum Di6s presence in plasma of 0.9–1.3 mg/mL.
Jackson et al. measured w10% (w2 mg/mL) Di6s in endogenous CS
and, considering as above the huge % variations, also in this case
it is very hard to observe any signiﬁcant value.
Along with detection limits, other factors may inﬂuence CS
recovery from plasma. For example, previous studies, contrary to
research in Ref. 1, accurately avoid the use of heparin (a polysaccha-
ride with similar anionic properties to CS), interfering in particular
with the extraction procedures. Furthermore, Jackson et al.
measured a CS endogenous amount of w20 mg/mL1, virtually 2–4
timesmore than several other studies performed by various analyt-
ical approaches [see Refs. 2 and 3]. Additionally, due to the anionic
properties of these macromolecules, absorbed CSmay interact with
several blood components, in particular with endothelium
reported, for example, to have the power to remove up to 80%
heparin from circulation after administration7. Finally, part of the
absorbed CS reaching the plasma compartment may be rapidly
taken up by liver cells where polysaccharides are most recovered
in experimental animals8.
According to the above-illustrated considerations and the data
available in International Scientiﬁc Literature, the statement
reported in the paper of Jackson et al.1 should be changed to the
more correct statement “no evidence for absorption of oral CS
into the circulation under any dosing regimen has been found under
the experimental conditions used in this study”.
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